KEYNOTE-905 ad hoc analysis:

Back to meeting Original

Back to meeting

Kohji Takemura, MD· @KohjiToncol · X·2026-10-23 20:35· 2 days agoScore70

KEYNOTE-905

Body

KEYNOTE-905 ad hoc analysis:

EV + pembrolizumab vs pembrolizumab alone suggests that EV plays a key role in the neoadjuvant setting.

But is adjuvant EV really necessary?

Hopefully, VOLGA will provide some clues tomorrow!

#ESMO26

229 views · 1 like · 2 reposts · 0 replies

Conference abstracts

4733Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895matched by - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

Source: Kohji Takemura, MD · x.com